COVID-19 vaccines from the likes of Pfizer Inc.Moderna, Inc., AstraZeneca PLC and Sanofi are hogging the headlines this week but Merck KGaA has working behind the scenes on over 50 vaccine programs, according to CEO Stefan Oschmann.
Merck KGaA Plays Key Supporting Role For Coronavirus Vaccines
Posts Strong Q3 Sales Growth
The German drugmaker is seeing growing demand for its services from peers in the pharma world that are looking to develop vaccines to tackle the COVID-19 pandemic.

More from Earnings
On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.